Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com

Dallas, Tx (PRWEB) January 20, 2015

The report ” Muscular Dystrophy Pipeline Review, H2 2014″ provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dystrophy-pipeline-review-h2-2014-market-report.html .

It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. Companies discussed in this Muscular Dystrophy Pipeline Review H2 2014 report include Acceleron Pharma, Inc., aTyr Pharma, Inc., Benitec Biopharma Limited, Bioblast Pharma Ltd., Calzada Limited, Evotec AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Genethon, Genzyme Corporation, Isis Pharmaceuticals, Inc., Marina Biotech, Inc., Novogen Limited, Prosensa Therapeutics B.V., Prothelia, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Valentia Biopharma S.L., Zambon Company S.p.A. Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=256231 .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Table of Contents

List of Tables

Number of Products under Development for Ischemia, H2 2014 15

Number of Products under Development for Ischemia – Comparative Analysis, H2 2014 16

Number of Products under Development by Companies, H2 2014 18

Number of Products under Development by Companies, H2 2014 (Contd..1) 19

Number of Products under Development by Companies, H2 2014 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2014 22

Comparative Analysis by Late Stage Development, H2 2014 23

Comparative Analysis by Clinical Stage Development, H2 2014 24

Comparative Analysis by Early Stage Development, H2 2014 25

Comparative Analysis by Unknown Stage Development, H2 2014 26

Products under Development by Companies, H2 2014 27

Products under Development by Companies, H2 2014 (Contd..1) 28

Products under Development by Companies, H2 2014 (Contd..2) 29

Products under Development by Companies, H2 2014 (Contd..3) 30

Products under Investigation by Universities/Institutes, H2 2014 31

Ischemia – Pipeline by Alize Pharma SAS, H2 2014 32

Ischemia – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 33

Ischemia – Pipeline by AnGes MG, Inc., H2 2014 34

Ischemia – Pipeline by Apceth GmbH & Co. KG, H2 2014 35

Ischemia – Pipeline by Athersys, Inc., H2 2014 36

Ischemia – Pipeline by Baxter International Inc., H2 2014 37

Ischemia – Pipeline by Cellmid Limited, H2 2014 38

Ischemia – Pipeline by CoDa Therapeutics, Inc., H2 2014 39

Ischemia – Pipeline by DNAVEC Corporation, H2 2014 40

Ischemia – Pipeline by GlaxoSmithKline plc, H2 2014 41

Ischemia – Pipeline by Hemostemix Ltd, H2 2014 42

Ischemia – Pipeline by Human Stem Cells Institute, H2 2014 43

Ischemia – Pipeline by IntelliCell BioSciences Inc., H2 2014 44

Ischemia – Pipeline by Juventas Therapeutics, Inc., H2 2014 45

Ischemia – Pipeline by Kasiak Research Pvt. Ltd., H2 2014 46

Ischemia – Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 47

Ischemia – Pipeline by Mast Therapeutics, Inc., H2 2014 48

List of Figures

Number of Products under Development for Ischemia, H2 2014 15

Number of Products under Development for Ischemia – Comparative Analysis, H2 2014 16

Number of Products under Development by Companies, H2 2014 17

Number of Products under Investigation by Universities/Institutes, H2 2014 21

Comparative Analysis by Clinical Stage Development, H2 2014 24

Comparative Analysis by Early Stage Products, H2 2014 25

Assessment by Monotherapy Products, H2 2014 68

Number of Products by Top 10 Targets, H2 2014 69

Number of Products by Stage and Top 10 Targets, H2 2014 69

Number of Products by Top 10 Mechanism of Actions, H2 2014 71

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 71

Number of Products by Top 10 Routes of Administration, H2 2014 73

Number of Products by Stage and Top 10 Routes of Administration, H2 2014 73

Number of Products by Top 10 Molecule Types, H2 2014 75

Number of Products by Stage and Top 10 Molecule Types, H2 2014 75

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.







More Compare Offers Press Releases

Leave a Reply

Your email address will not be published. Required fields are marked *